-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
GlaxoSmithKline announced that the FDA has accelerated approval of Belantamab mafodotin-blmf for the treatment of adult patients with recurrent or recurrent multiple myeloma who have received at least four previous treatments, including anti-CD38 monoclonal antibodies, protease inhibitors, and immunomodants.
photo Source: Blenrep is an antibody-drug concatile (ADC) that targets B-cell mature antigens (B Cell Maturation Antigens), a drug that connects anti-BCMA monoantimmune to the cytotoxic drug monomethyl auristatin-F via a connecting subn.
anti-BCMA monoantigens are targeted to bind to BCMA on the surface of multiple myeloma cells, which are then internalized by tumor cells to release non-permeable cytotoxic drugs to play an anti-tumor role.
GSK noted that FDA approval makes Blenrep the world's first antibody-drug concoant to target BCMA.
the FDA Advisory Group approved the drug by a vote of 12 to 0.
but the eye toxicity of Blenrep was observed in key DREAM-2 trials.
corneal lesions were the most common adverse events in the study, with a total rate of 71%, while 44% of patients experienced at least one serious corneal lesion at a dose of 2.5 mg/kg.
Recently, the European Medicines Agency's Human Medicines Committee recommended that Blunrep be granted conditional market approval to treat patients with recurrent and recurrent multiple myeloma who are ineffective in the treatment of immunomodants, protease inhibitors and CD-38 monoclonal antibodies.
.
